One targets twice-weekly distributions; the other targets ~12%
annually with monthly payouts. ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏



 

[Morning Watchlist]

_You are receiving this email because you are subscribed to BEHIND THE
MARKETS. If you no longer wish to receive these emails,
please unsubscribe
[[link removed]] here._

_Prefer to view this content on our website? Click here.
[[link removed]]
_

-------------------------

THESE OPTIONS-BASED ETFS PAY RESPECTABLE YIELDS

One of the simplest ways to build passive income is by owning
dividend-paying ETFs. But in recent years, a fast-growing category has
taken the income conversation in a new direction: OPTIONS-BASED INCOME
ETFS.

Instead of relying primarily on stock dividends, these funds seek to
generate cash flow from OPTION PREMIUMS - most commonly through
covered calls, call spreads, or other systematic options strategies.
The appeal is obvious: option premium can be harvested in many market
environments, and some ETFs are structured to distribute that premium
to shareholders on a frequent schedule.

The trade-offs are just as important as the yield. Options-based
income strategies can CAP UPSIDE during sharp rallies, and
distributions often include significant RETURN OF CAPITAL (ROC), which
can reduce NAV over time. In other words, these funds can be excellent
income tools when used appropriately, but they are not “free
yield.”

With that context, here are two options-based ETFs that stand out for
FREQUENCY OF DISTRIBUTIONS and INCOME ORIENTATION heading into 2026.

-------------------------

_Med-x Inc_

MED-X IS PREPARING FOR A POTENTIAL NASDAQ LISTING (TICKER: MXRX) —
BUT THE REAL OPPORTUNITY IS RIGHT NOW, BEFORE GLOBAL VALIDATION
RESHAPES THE VALUATION.
[[link removed]]

In independent lab studies, Med-X’s all-natural pesticide
Nature-Cide has outperformed chemical competitors in key use cases —
delivering powerful results without toxic tradeoffs.

Now comes a potential industry-defining catalyst:
Med-X is pursuing WORLD HEALTH ORGANIZATION PRE-QUALIFICATION, aiming
to become the first botanical pesticide recognized at a global
public-health level.

With the global biopesticide market projected to grow nearly 3× by
2030 — from $5.8B to $17.6B — WHO validation could unlock access
to governments, agriculture, and mosquito-control programs worldwide.

Already sold through AMAZON, WALMART, AND KROGER, and expanding across
41 international markets, Med-X is positioning itself for its next
major chapter.

SIMPLER. SAFER. MORE EFFECTIVE PESTICIDES.

👉 BECOME A MED-X SHAREHOLDER AT $4 PER SHARE BEFORE NASDAQ PLANS
UNFOLD
[[link removed]]

-------------------------

ETF: DEFIANCE NASDAQ 100 LIGHTNINGSPREAD INCOME ETF (SYM: QLDY)

QLDY is designed for investors who want FREQUENT INCOME tied to the
Nasdaq-100 without necessarily owning the underlying Nasdaq-100 stocks
directly.

According to Defiance, QLDY is an actively managed ETF seeking current
income (primary objective) and capital appreciation (secondary
objective). It is built around a proprietary “LightningSpread”
approach that combines:

*
SYNTHETIC NASDAQ-100 EXPOSURE using deep in-the-money call options

*
DAILY OPTION PREMIUM GENERATION via systematic sales of
ZERO-DAYS-TO-EXPIRATION (0DTE) PUT SPREADS

Importantly, the fund explicitly notes that investors do NOT have
rights to dividends from Nasdaq-100 constituents because the exposure
is obtained through options rather than directly holding the stocks.

WHAT MAKES QLDY DIFFERENT: TWICE-WEEKLY DISTRIBUTIONS

Defiance describes QLDY as the first ETF designed to make
distributions TWICE WEEKLY, aiming to deliver more frequent income
than traditional monthly or quarterly income funds.

The fund’s posted distribution schedule shows frequent declaration
and payable dates consistent with that high-frequency intent. For
example, recent payouts listed on the sponsor page include:

*
$0.1830 (payable 01/15/2026)

*
$0.1824 (payable 01/12/2026)

COSTS, PRICE, AND “HEADLINE YIELD” CONSIDERATIONS

Defiance lists QLDY’s EXPENSE RATIO AT 1.04%, with a fund inception
date of 09/17/2025.
As of 01/16/2026, Defiance reported a NAV OF $46.58 and a CLOSING
PRICE OF $46.50.

The sponsor page also shows a DISTRIBUTION RATE OF 40.00% (as
displayed on the fund page as of mid-January 2026).
However, it is essential to interpret that number correctly:
distribution rates in options-income ETFs can be heavily influenced by
recent payouts, volatility, and NAV movement—so they can change
materially over time.

THE CRITICAL DETAIL MOST INVESTORS MISS: ROC RISK

Defiance also includes an explicit warning that QLDY distributions can
vary significantly and are not guaranteed. Even more important, the
sponsor page notes that QLDY’s distributions (for the referenced
19a-1 notice) were shown as 100% RETURN OF CAPITAL, and it cautions
that ROC reduces NAV and trading price over time and “can result in
losses on an investment.”

Bottom line on QLDY: If you want VERY FREQUENT CASH FLOW tied to
Nasdaq-100-style exposure, QLDY is purpose-built for that. But you
should go in with eyes open—this is an options strategy with
meaningful complexity, capped upside potential, and a strong
likelihood of ROC-heavy distributions.

-------------------------

_TradeSmith_

HERE’S THE BEST DAY TO BUY STOCKS
[[link removed]]

Did you know the S&P 500 has a 100% history of soaring, beginning on
one particular
date every year?

We call this “The Green Day Phenomenon.” It works on 5,000 stocks.

For example, Nvidia has a 93% history of soaring beginning every
January 26. This has held true for 15 years, through bull and bear
markets.

CLICK HERE TO SEE THE GREEN DAYS FOR 5 MAJOR STOCKS TODAY.
[[link removed]]
_Clicking the link above will opt you into communication from
TradeSmith, including the TradeSmith Daily daily E-Letter._

-------------------------

ETF: YIELDMAX TARGET 12 BIG 50 OPTION INCOME ETF (SYM: BIGY)

BIGY takes a different approach. Instead of synthetic index exposure
and 0DTE put spreads, BIGY targets income by holding a diversified
portfolio of the largest U.S. companies and generating premium through
a SYSTEMATIC CALL OPTION / CALL SPREAD OVERLAY.

YieldMax describes BIGY as an actively managed ETF that seeks a TARGET
ANNUALIZED DISTRIBUTION OF 12% and capital appreciation via direct
investments in a portfolio of 50 of the largest publicly traded U.S.
companies by market cap, selected with attention to liquidity and
volatility.

The fund seeks to generate income primarily by SELLING CALL OPTIONS
AND CALL SPREADS on its portfolio holdings, while also pursuing
capital appreciation via equity exposure.

STRUCTURE AND FUND DETAILS

On the sponsor site, BIGY lists:

*
FUND INCEPTION: 11/20/2024

*
GROSS EXPENSE RATIO: 1.09%

*
DISTRIBUTION RATE: 12.00% (as of 12/30/2025 on the sponsor page)

*
The fund “intends to pay out dividends and interest income, if any,
monthly.”

As of JANUARY 20, 2026, BIGY was trading around $51.31.

RECENT DISTRIBUTIONS (MONTHLY)

YieldMax provides a distribution table on the BIGY page. Recent
entries include:

*
$0.5325 declared 12/30/2025, payable 01/02/2026

*
$0.5331 declared 12/02/2025, payable 12/04/2025

THE BIGY TRADE-OFF: UPSIDE CAP AND ROC

YieldMax is very direct about the risk profile: because BIGY sells
options, ITS EXPOSURE TO GAINS IS CAPPED, while it remains exposed to
declines in the underlying holdings (which may not be fully offset by
option income).

Also, like many options-income ETFs, BIGY’s distribution composition
can include substantial return of capital. The sponsor page notes that
the MOST RECENT DISTRIBUTION (12/30/2025) contained 86.47% RETURN OF
CAPITAL and 13.53% INCOME, and it cautions that ROC can decrease NAV
and trading price over time.

WHY BIGY CAN WORK IN 2026

BIGY’s holdings are oriented toward the largest, most liquid U.S.
companies—many of which are tied to the AI and data-center capex
cycle. While you do not need an AI thesis to own BIGY, the macro
tailwind helps explain why large-cap growth leadership (and options
premiums on those names) remains a central income theme.

On the broader AI backdrop, Grand View Research estimates the global
AI market was $390.91B IN 2025 and projects it could reach $3,497.26B
BY 2033.

Bottom line on BIGY: BIGY is designed as a MONTHLY HIGH-INCOME vehicle
built on a diversified portfolio of mega-cap U.S. stocks plus a
call-selling overlay. It can be a practical “income sleeve,” but
investors should understand the upside cap and ROC-heavy distribution
dynamics.

-------------------------

_Weiss Ratings_

STRANGE PICTURE SIGNALS MARKET SHIFT IN 2026?
[[link removed]]

Take a look at this picture:

[RPL stock exchange]
[[link removed]]

It's the New York Stock Exchange right after the 1229 crash.

But did you know …

A strange investment secret — discovered just a few short weeks
before this image was taken — correctly predicted the crash?

Even crazier, this secret accurately called every major financial
event in recent history …

Now, this secret is signaling something very scary is about to hit the
stock market in 2026 …

CLICK HERE TO FIND OUT MORE.
[[link removed]]

-------------------------

_Are there any other income-focused ETFs you swear by? What other
sectors of the market are you currently interested in? Hit "reply" to
this email and let us know your thoughts!_

Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431

Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the
Markets. For more information about our privacy practices, please
review our Privacy Policy
[[link removed]]
or our Legal Notices.
[[link removed]]

We are issuing this disclosure in compliance with Section 17(b) of the
Securities Act, which requires us to disclose any compensation
received or expected to be received in cash or in kind in connection
with the purchase or sale of any security.

We would like to inform you that this is a paid advertisement for
Med-X's Regulation A+ Offering offering and we have received or expect
to receive compensation in connection with the disbursing this
communication for Med-X . The compensation could consist of $1,000 or
more and was received/will be received from Investing Media Solutions.

This communication should not be considered as an endorsement of Med-X
and we are not responsible for any errors or omissions in any
information provided about by or about Med-X.

We encourage you to conduct your own due diligence and research before
making any investment decisions. You should also consult with a
financial advisor before making any investment decisions.

This disclosure is made as of 01/21/2026.

Behind the Markets
[[link removed]]

Unsubscribe
[[link removed]]

invisiblelink
[[link removed]]